Australia - English - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - selexipag, quantity: 1600 microgram - tablet, film coated - excipient ingredients: hypromellose; titanium dioxide; magnesium stearate; mannitol; iron oxide yellow; carnauba wax; hyprolose; maize starch; propylene glycol; iron oxide black; iron oxide red - uptravi is indicated for the treatment of:,- idiopathic pulmonary arterial hypertension;,- heritable pulmonary arterial hypertension;,- pulmonary arterial hypertension associated with connective tissue disease;,-pulmonary arterial hypertension associated with congenital heart disease with repaired shunts;,-pulmonary arterial hypertension associated with drugs and toxins;,in patients with who functional class ii, iii or iv symptoms

Australia - English - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - selexipag, quantity: 1200 microgram - tablet, film coated - excipient ingredients: titanium dioxide; hyprolose; maize starch; propylene glycol; iron oxide red; mannitol; hypromellose; magnesium stearate; carnauba wax; iron oxide black - uptravi is indicated for the treatment of:,- idiopathic pulmonary arterial hypertension;,- heritable pulmonary arterial hypertension;,- pulmonary arterial hypertension associated with connective tissue disease;,-pulmonary arterial hypertension associated with congenital heart disease with repaired shunts;,-pulmonary arterial hypertension associated with drugs and toxins;,in patients with who functional class ii, iii or iv symptoms

Australia - English - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - selexipag, quantity: 1000 microgram - tablet, film coated - excipient ingredients: mannitol; hypromellose; titanium dioxide; maize starch; hyprolose; magnesium stearate; propylene glycol; iron oxide red; carnauba wax; iron oxide yellow - uptravi is indicated for the treatment of:,- idiopathic pulmonary arterial hypertension;,- heritable pulmonary arterial hypertension;,- pulmonary arterial hypertension associated with connective tissue disease;,-pulmonary arterial hypertension associated with congenital heart disease with repaired shunts;,-pulmonary arterial hypertension associated with drugs and toxins;,in patients with who functional class ii, iii or iv symptoms

Australia - English - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - selexipag, quantity: 200 microgram - tablet, film coated - excipient ingredients: iron oxide yellow; carnauba wax; maize starch; magnesium stearate; hyprolose; propylene glycol; mannitol; titanium dioxide; hypromellose - uptravi is indicated for the treatment of:,- idiopathic pulmonary arterial hypertension;,- heritable pulmonary arterial hypertension;,- pulmonary arterial hypertension associated with connective tissue disease;,-pulmonary arterial hypertension associated with congenital heart disease with repaired shunts;,-pulmonary arterial hypertension associated with drugs and toxins;,in patients with who functional class ii, iii or iv symptoms

Australia - English - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - selexipag, quantity: 400 microgram - tablet, film coated - excipient ingredients: hyprolose; hypromellose; carnauba wax; magnesium stearate; mannitol; maize starch; propylene glycol; titanium dioxide; iron oxide red - uptravi is indicated for the treatment of:,- idiopathic pulmonary arterial hypertension;,- heritable pulmonary arterial hypertension;,- pulmonary arterial hypertension associated with connective tissue disease;,-pulmonary arterial hypertension associated with congenital heart disease with repaired shunts;,-pulmonary arterial hypertension associated with drugs and toxins;,in patients with who functional class ii, iii or iv symptoms

Australia - English - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - selexipag, quantity: 600 microgram - tablet, film coated - excipient ingredients: iron oxide red; hyprolose; carnauba wax; magnesium stearate; titanium dioxide; hypromellose; propylene glycol; mannitol; maize starch; iron oxide black - uptravi is indicated for the treatment of:,- idiopathic pulmonary arterial hypertension;,- heritable pulmonary arterial hypertension;,- pulmonary arterial hypertension associated with connective tissue disease;,-pulmonary arterial hypertension associated with congenital heart disease with repaired shunts;,-pulmonary arterial hypertension associated with drugs and toxins;,in patients with who functional class ii, iii or iv symptoms

Australia - English - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - epoprostenol sodium, quantity: 531 microgram (equivalent: epoprostenol, qty 500 microgram) - powder - excipient ingredients: arginine; sodium hydroxide; sucrose - veletri is indicated for the long-term treatment, via continuous intravenous infusion, in who functional class iii or class iv patients with:,? idiopathic pulmonary arterial hypertension,? familial pulmonary arterial hypertension,? pulmonary arterial hypertension associated with the scleroderma spectrum of diseases

Australia - English - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - epoprostenol sodium, quantity: 1.593 mg (equivalent: epoprostenol, qty 1.5 mg) - powder - excipient ingredients: arginine; sodium hydroxide; sucrose - veletri is indicated for the long-term treatment, via continuous intravenous infusion, in who functional class iii or class iv patients with:,? idiopathic pulmonary arterial hypertension,? familial pulmonary arterial hypertension,? pulmonary arterial hypertension associated with the scleroderma spectrum of diseases

Australia - English - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - macitentan, quantity: 10 mg - tablet, film coated - excipient ingredients: sodium starch glycollate type a; magnesium stearate; microcrystalline cellulose; polysorbate 80; povidone; lactose monohydrate; titanium dioxide; purified talc; xanthan gum; polyvinyl alcohol; lecithin - opsumit, as monotherapy or in combination with approved pah treatments (phosphodiesterase-5 inhibitors or inhaled prostanoids), is indicated for the treatment of: ?idiopathic pulmonary arterial hypertension ?heritable pulmonary arterial hypertension ?pulmonary arterial hypertension associated with connective tissue disease ?pulmonary arterial hypertension associated with congenital heart disease with repaired shunts in patients with who functional class ii, iii or iv symptoms.

Australia - English - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - miglustat, quantity: 100 mg - capsule, hard - excipient ingredients: magnesium stearate; povidone; sodium starch glycollate; titanium dioxide; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; strong ammonia solution; ethanol absolute; iron oxide black; ethanol; shellac; sulfuric acid; potassium hydroxide; industrial methylated spirit; ammonia; sorbitan monolaurate; gelatin; sodium lauryl sulfate - zavesca is indicated for the oral treatment of patients with mild to moderate type 1 gaucher disease, for whom enzyme replacement therapy is not a therapeutic option. zavesca is indicated for the treatment of the progressive neurological manifestations in adult and paediatric patients with niemann-pick type c disease.